1. Pink Sheet
  2. >>Geography
  3. >>Europe

EMA Approves Three Oncology Drugs, Rejects One

 
• By Faraz Kermani

Cancer drugs had a triumphant day at the European Medicines Agency on July 20, led by Pfizer’s Xalkori, with only one (Celgene’s Istodax) failing to make the grade.

It has been a good day for cancer drugs in the EU, with the European Medicines Agency giving the nod to three and panning only one. Pfizer Inc.’s Xalkori (crizotinib), Takeda Pharmaceutical Co. Ltd.’s Adcetris (brentuximab vedotin) and Janssen Inc.’s Dacogen (decitabine) all made the grade, while Celgene Corp.’s Istodax (romidepsin) fell by the wayside.

In an era where new lung cancer therapies are few and far between, the EMA decided to give Xalkori the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

Consumer Groups Have A ‘Radical Transparency’ List For US FDA’s PDUFA VIII

 
• By Sarah Karlin-Smith

Development of the user fee commitment letter largely takes place behind closed doors between industry and FDA. Outside groups see the upcoming negotiation cycle as a chance to change this and other agency information blocks by reminding Commissioner Makary of his commitment to transparency.

Beijing City Releases AI Action Plan Including Drug Regulation

 
• By Xu Hu

Amid the wait for an action plan to apply AI tools to drug regulation at the national level in China, capital city Beijing has released its own vision of scenarios for the technology in the healthcare sector.

Senate Bill Would Boost Oversight Of US FDA User Fee Program Following Trump Reorganization

 
• By Sarah Karlin-Smith

Senate appropriators also put FDA on notice regarding recent meetings and compliance with the Federal Advisory Committees Act, signal positive news on rare pediatric diseases, and offer hints of other agency areas they have close eyes on.